Anxiety and Medical Marijuana: A Large Effect That Disappeared After Correction

• How much evidence. 3 works from 2020 to 2026, all listed in the table below along with the model.
• What was not demonstrated. This is an indication where two large studies say different things, and this discrepancy itself is information. The latest meta-analysis found no significant effect on anxiety symptoms, while an older one found a very large effect that disappeared after correction.
• What you won’t find here. Dosage recommendations or strain indications. The selection is determined by the attending physician, and cannabis flower is a raw material dispensed only by prescription.
• How to read this. A study result in rodents or in cell culture does not directly translate to a patient taking flower, and the column with the model indicates what the work was actually about.

What Do Studies Say About Cannabis and Anxiety?

Three things at once, and this is the main information here. A meta-analysis from 2020 found a very large reduction in anxiety symptoms, which ceased to be significant after correction for publication bias. A review from 2026 found no significant effects regarding anxiety. A work from 2025 sees moderate effects and itself calls the evidence low quality.

The oldest of these works (PMID:32827809) is a systematic review with a meta-analysis of randomized studies in anxiety disorders: fourteen trials, one thousand five hundred forty-eight people. The raw result is a reduction of symptoms by 1.85 standard deviations, with a confidence interval from minus 2.61 to minus 1.09 and no significant increase in adverse events. The authors themselves reported a significant publication bias, and after correcting for it, the anxiolytic effect ceased to be statistically significant.

A review published in 2026 in The Lancet Psychiatry (PMID:41856154) included fifty-four randomized studies and two thousand four hundred seventy-seven people. At anxiety endpoints, it did not show significant effects. The work from 2025 (PMID:40956670) gathered twenty-one trials with placebo and divided them by preparation, as discussed below, and assessed the overall evidence as low quality.

This is an indication where two large studies say different things, and this discrepancy itself is information. The latest meta-analysis found no significant effect on anxiety symptoms, while an older one found a very large effect that disappeared after correction for publication bias. The evidence that survived pertains to purified substances with known doses administered in a disorder diagnosed by a psychiatrist, not to the flower described by strain name. Anxiety can also be an adverse effect of the raw material itself, increasing with dosage.

What Is Publication Bias and Why Did It Change This Result?

Publication bias is an unequal chance of publication: studies with positive results are published more often and faster than those with no results. The available collection in databases is skewed, and a meta-analysis averaging this collection inherits the bias along with it.

It is detected by statistical methods, and then it is estimated what the result would look like if the missing works were included in the set. In the 2020 review, this procedure reversed the verdict: before correction, the effect was very large; after correction, it ceased to be statistically significant. This does not mean that anyone was wrong or that something was hidden. It means that part of the material on which the number 1.85 stood was probably never published.

This is where the discrepancy between what is read online and what is stated in the publication comes from. The raw number is striking and easy to quote, while the sentence about correction lies a few paragraphs later and gets lost in the summary. So when a strain description promises anxiolytic effects and refers to a meta-analysis, it usually repeats the first half of the same work without the second. The authors themselves stated directly that the available evidence does not justify routine use of these preparations.

What Strain Characteristics Matter Here?

No characteristic recorded in the strain name has been tested in these works. Purified substances with known doses were studied, not flower described by trade name, so the differences visible in the results pertain to the chemical composition of the preparation, not the cultivar from which the pharmaceutical raw material comes.

The separation of preparations in the 2025 work (PMID:40956670) is the most interesting here. For preparations with pure or enriched cannabidiol, the overall result was not significant (minus 0.40, confidence interval from minus 0.84 to 0.03), and only the subgroup of pure cannabidiol showed a moderate effect (minus 0.61, from minus 1.15 to minus 0.07). For preparations with a predominance of tetrahydrocannabinol, the result was minus 0.65 (from minus 1.06 to minus 0.24), and for mixtures of both compounds, it was not significant. All these numbers come from a systematic review with a meta-analysis of twenty-one trials with placebo, and their authors noted that the trials were small and the study designs heterogeneous.

At the raw material level, a sensible distinction thus ends at chemotype, meaning which compound predominates in the composition. The terpene profile is sometimes associated with calming in strain descriptions, but none of the three discussed works tested a single terpene or the entire profile. Separately, we write about linalool and limonene, and in both cases, the clinical material regarding anxiety is poor. Additionally, there is the issue measured in this cluster: for the same strain, two Polish sources can provide different compositions, so the profile can be a feature of the description rather than a feature of the plant.

How to Read the Numbers from These Meta-Analyses?

Three concepts are sufficient. Standard deviation measures the strength of the effect in units of dispersion of results, the confidence interval shows the range within which the true value lies, and the odds ratio compares the risk in two groups. When the interval includes zero, the result is called statistically insignificant, and the absence of an effect cannot be excluded.

In the 2025 work, the overall result for cannabidiol preparations reached 0.03 on the positive side of zero, so despite the negative average, it remained insignificant. The same principle explains why the correction in the 2020 work was enough to consider the effect insignificant, even though the average still indicated a reduction in symptoms. The number itself, therefore, says nothing until it stands next to an interval.

An odds ratio of 1.75 for adverse events translates in the 2026 review to one additional person with an event for every seven treated. Such a conversion says more than the odds ratio itself because it describes the scale at which the difference appears in people. Additionally, there is the assessment of the certainty of the evidence: low in the 2025 work, burdened by a high risk of systematic error in 44 percent of the studies in the 2026 review, distorted by publication bias in the 2020 work.

What Does the Doctor Decide, and What Does the Patient Decide?

The attending physician decides everything related to treatment. Cannabis flower is a pharmaceutical raw material dispensed by prescription in the Rpw category, so the form, dosage, and route of administration are determined by the prescription, not by the strain description, ranking online, or the patient’s choice.

In this indication, there is also the diagnosis. The evidence mentioned above was gathered from individuals with a disorder diagnosed by a psychiatrist, not from individuals who self-identified their state as anxiety. Diagnosis is a medical act, and it is from it that everything else begins: without it, the numbers from the meta-analyses have nothing to refer to.

The patient has a role that no one can play for them. They know the full list of medications taken, including anxiolytics, and they will notice that after a dosage change, symptoms went in the other direction. Reporting an adverse effect also comes from them or from the pharmacist. None of this is a choice of therapy, but rather the material on which the doctor bases their choice.

This division also explains what cannot be on the informational page. We describe the state of evidence along with its limits and do not indicate the strain, form, or method of administration. Pharmaceutical law does not allow addressing advertising messages about prescription drugs to the general readership, and therapeutic advice requires examining a specific person by a doctor.

How Quickly and How Long Does the Raw Material Work When Administered in Different Ways?

This is determined by the method of intake, not the cultivar. Inhalation through a vaporizer starts effects measured in minutes and an episode contained within a few hours, while the ingested raw material responds with a delay and lasts for a larger part of the day. In anxiety, this difference weighs more than the name on the label.

The route of administration determines the course more than the strain itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, intensity increases for another ten to thirty minutes, and the whole effect passes within two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two, and the episode lasts six, sometimes eight hours. This leads to the most common mistake with oral administration: who thinks after thirty minutes that nothing is happening and adjusts the dose will receive both doses at once. The above intervals describe the route of administration, not the strain; pharmacokinetic studies for a single cultivar have not been published.

In anxiety, this spread has practical consequences because tension prompts checking whether it is already working, and with oral administration, such checking comes too early. None of the three discussed works compared routes of administration with each other, so the above intervals describe physiology, not the results of studies on anxiety.

What Adverse Effects Were Reported with Cannabis Use in This Indication?

Two of the three works counted them directly, and they came out differently. In the 2020 review, the increase in adverse events was not significant, while in the 2026 review, the odds ratio for any adverse event was 1.75, meaning one additional person with an event for every seven treated.

The number from 2026 comes from a systematic review with a meta-analysis of randomized studies, including fifty-four trials and two thousand four hundred seventy-seven people; its confidence interval runs from 1.25 to 2.46, and a high risk of systematic error was present in 44 percent of the included studies. The lack of a significant increase from 2020 comes from a review of fourteen randomized trials conducted in anxiety disorders. The work from 2025 mentions safety and tolerance among the studied endpoints, but does not provide numbers for them.

Separately, it stands that anxiety itself can be an adverse effect of the raw material and increases with dosage. In this indication, the same symptom thus stands on both sides: once as a reason to reach for the raw material, and once as a possible consequence of its administration.

Reports of adverse effects are collected for a medicinal product with a batch number, not for the strain name, so the following pertains to cannabis flower as a group of raw materials. The most commonly reported symptoms are dry mouth, red eyes, and increased heart rate. Less frequently described are dizziness upon rapid standing, daytime drowsiness, and transient worsening of short-term memory, as well as anxiety increasing with dosage. A separate issue is medications taken concurrently, especially anxiolytics and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not the description of the plant. We do not provide the frequency of these symptoms numerically because public compilations for cannabis flower in Poland do not separate them by individual products.

Why Do Strain Descriptions Promise More Than Studies Show?

Because they describe a product, not a study result. The strain name is a trade label, not a variable measured in a clinical trial, so the effects attributed to it usually come from user reports and sales materials, not from a placebo comparison conducted under blinded trial conditions.

Three different things carry the same name. In studies, purified substances with known doses were administered. In the pharmacy, flower described by strain name is dispensed by prescription, the contents of which are not measured at the patient’s bedside. In the store, there is hemp flower, sold over the counter and not covered by any of the discussed studies.

The list of strains available in Polish pharmacies is maintained in a separate entry and we do not assign indications to strains there, as the register lists positions, not applications. The same applies to sleep, where the evidence is different from that for anxiety and requires its own discussion. The material is informational and does not replace medical advice.

The practical conclusion from this page is modest and is meant to be so. In anxiety, it is worth checking whether the cited number comes from before or after correction, which preparation it pertains to, and how many people it was measured on. The three works cited above answer these questions themselves, as each provides its limitations in the same place as the result.

Frequently Asked Questions

Does Medical Marijuana Treat Anxiety Disorders?

There is no evidence for that. The latest meta-analysis found no significant effect on anxiety symptoms, an older one found a very large effect that disappeared after correction for publication bias, and the third work describes moderate effects with evidence described in its own words as low quality.

Where Does the Number 1.85 Repeated in Strain Descriptions Come From?

From the raw result of the meta-analysis from 2020, which included fourteen randomized studies and one thousand five hundred forty-eight people. However, the same work reports a significant publication bias, and after correcting for it, the effect ceases to be statistically significant.

What Is Publication Bias?

An unequal chance of publication. Studies with positive results appear more often than those with no results, so the collection available in databases inflates the average that the meta-analysis calculates. There are methods for estimating this distortion and correcting the result for it.

Can Pharmacy Flower Increase Anxiety?

Anxiety can be an adverse effect of the raw material itself and increases with dosage. Therefore, in this indication, the same symptom appears on both sides: as a reason to reach for the raw material and as a possible consequence of its administration.

Has Any Strain Been Tested for Anxiety?

No. The discussed studies administered purified substances with known doses, not flower described by trade name. Differences in results pertain to the chemical composition of the preparation, not the cultivar, and cannot be transferred to a single name from the pharmacy price list.

Did Cannabidiol Perform Differently Than Tetrahydrocannabinol?

In the 2025 review, the overall result for cannabidiol preparations was not significant, and a moderate effect appeared only in the subgroup of pure cannabidiol. Preparations with a predominance of tetrahydrocannabinol yielded a moderate result, while mixtures of both compounds were not significant.

Who Decides on the Use of Flower for Anxiety?

The attending physician. The raw material is dispensed by prescription in the Rpw category, the diagnosis of anxiety disorder is made by a psychiatrist, and the form, dosage, and route of administration are determined by the prescription. The informational page does not replace any of these actions.

Editorial text of the ubucha.pl service, ubucha editorial team.